Drug Trial Radar · NCT02595073
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Dec 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Sep 4, 2015
Primary completion
Jan 17, 2017
Study completion Aug 29, 2017
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis
Conditions
- Atopic Dermatitis
Interventions
DSXSDrug
Active treatment
PlaceboDrug
Placebo treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Patients in Each Treatment Group That Have Clinical SuccessTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taro Pharmaceuticals USA Inc.
Hawthorne, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.